|
|
||||||||
Correspondence to:
Catherine C. Hedrick, at the Department of Endocrinology and Metabolism, MR-4, Room 5116, Lane Road, P.O. Box 801405, University of Virginia, Charlottesville, VA 22908., cch6n{at}virginia.edu (E-mail)
Studies with mice have revealed that increased expression of apolipoprotein A-II (apoA-II) results in elevations in high density lipoprotein (HDL), the formation of larger HDL, and the development of early atherosclerosis. We now show that the increased size of HDL results in part from an inhibition of the ability of hepatic lipase (HL) to hydrolyze phospholipids and triglycerides in the HDL and that the ratio of apoA-I to apoA-II determines HDL functional and antiatherogenic properties. HDL from apoA-II transgenic mice was relatively resistant to the action of HL in vitro. To test whether HL and apoA-II influence HDL size independently, combined apoA-II transgenic/HL knockout (HLko) mice were examined. These mice had HDL similar in size to apoA-II transgenic mice and HLko mice, suggesting that they do not increase HDL side by independent mechanisms. Overexpression of apoA-I from a transgene reversed many of the effects of apoA-II overexpression, including the ability of HDL to serve as a substrate for HL. Combined apoA-I/apoA-II transgenic mice exhibited significantly less atherosclerotic lesion formation than did apoA-II transgenic mice. These results were paralleled by the effects of the transgenes on the ability of HDL to protect against the proinflammatory effects of oxidized low density lipoprotein (LDL). Whereas nontransgenic HDL protected against oxidized LDL induction of adhesion molecules in endothelial cells, HDL from apoA-II transgenic mice was proinflammatory. HDL from combined apoA-I/apoA-II transgenic mice was equally as protective as HDL from nontransgenic mice.
Our data suggest that as the ratio of apoA-II to apoA-I is increased, the HDL become larger because of inhibition of HL, and lose their antiatherogenic properties. Hedrick, C. C., L. W. Castellani, H. Wong, and A. J. Lusis. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J. Lipid Res. 2001. 42: 563;570.
Supplementary key words:
atherosclerosis, lipoprotein, paraoxonase, transgenic mice
Copyright © 2001 by Lipid Research, Inc.
Original Article
In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions
Catherine C. Hedricka,
Lawrence W. Castellania,
Howard Wongd, and
Aldons J. Lusisa,b,c
a Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
b Department of Microbiology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095
c Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095
d Lipid Research Laboratory, Wadsworth VA Medical Center, Los Angeles, CA 90024
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. A. G. D. Silva, L. A. Schneeweis, S. C. Krishnan, X. Zhang, P. H. Axelsen, and W. S. Davidson The Structure of Apolipoprotein A-II in Discoidal High Density Lipoproteins J. Biol. Chem., March 30, 2007; 282(13): 9713 - 9721. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. L. Cervino, A. Darvasi, M. Fallahi, C. C. Mader, and N. F. Tsinoremas An Integrated in Silico Gene Mapping Strategy in Inbred Mice Genetics, January 1, 2007; 175(1): 321 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jayaraman, D. L. Gantz, and O. Gursky Kinetic Stabilization and Fusion of Apolipoprotein A-2:DMPC Disks: Comparison with apoA-1 and apoC-1 Biophys. J., April 1, 2005; 88(4): 2907 - 2918. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shi, H. Pei, J. J. Fischer, J. C. James, J. F. Angle, A. H. Matsumoto, G. A. Helm, and I. J. Sarembock Neointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility J. Lipid Res., November 1, 2004; 45(11): 2008 - 2014. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Reilly, S. Srinivasan, M. E. Hatley, M. K. Patricia, J. Lannigan, D. T. Bolick, G. Vandenhoff, H. Pei, R. Natarajan, J. L. Nadler, et al. 12/15-Lipoxygenase Activity Mediates Inflammatory Monocyte/Endothelial Interactions and Atherosclerosis in Vivo J. Biol. Chem., March 5, 2004; 279(10): 9440 - 9450. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Conde-Knape, A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase J. Lipid Res., December 1, 2002; 43(12): 2136 - 2145. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Su, S. Zhang, D. W. Nebert, L. Zhang, D. Huang, Y. Hou, L. Liao, and C. Xiao A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity J. Lipid Res., October 1, 2002; 43(10): 1595 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca Mechanisms of HDL deficiency in mice overexpressing human apoA-II J. Lipid Res., October 1, 2002; 43(10): 1734 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Jansen, A. J. M. Verhoeven, and E. J. G. Sijbrands Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res., September 1, 2002; 43(9): 1352 - 1362. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein J. Lipid Res., November 1, 2001; 42(11): 1727 - 1739. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |